Fusion IP high on drug success
Fusion IP, a company which attempts to make money from university research, has rocketed 35% this morning after encouraging results on a drugs trial in which it has a significant interest.
Fusion IP, a company which attempts to make money from university research, has rocketed 35% this morning after encouraging results on a drugs trial in which it has a significant interest.
Fusion has a 43.1% shareholding in Diurnal, a Cardiff-based firm looking to help patients suffering from cortisol deficiencies. Diurnal is attempting to develop Chronocort, a modified release therapy that delivers hydrocortisone in a manner that mimics the body's normal circadian rhythm (the body's natural 24-hour hormone cycle).
Often patients require lifelong treatment and Chronocort may be able to significantly improve their lives, Fusion IP said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The trial involved the administration to healthy volunteers of different formulations of Chronocort followed by blood measurements of hydrocortisone.
The company hopes to move into Phase II trials during 2012, with an estimated Phase II completion date of mid-2013.
Chronocort has already received two "Orphan Drug" designations from the European Medicines Agency, which affords10 years of market exclusivity in Europe.
Peter Grant, Operations Director for Fusion, commented: "it is hard to estimate what the value will be at the end of Phase 2, (however) it is notable there has been acquisition activity involving a similar drug in a comparable indication which attracted high value."
BS
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Reducing cash ISA limit will make lending difficult and expensive, warn providers
An open letter from the Building Societies Association has urged the chancellor to keep the cash ISA limit at £20,000. We look at whether a smaller cash ISA allowance will make it harder to get a mortgage or loan
-
Nvidia becomes world's first $4 trillion company
The AI boom has catapulted Nvidia’s share price to astronomic heights, becoming the world’s most valuable company and the first to pass the $4 trillion milestone